Drug Profile
Research programme: RNA interference therapeutics - Alnylam Pharmaceuticals/Vir Biotechnology
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Vir Biotechnology
- Class Anti-infectives; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Coronavirus infections; COVID 2019 infections
- No development reported Infections
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Infections in USA (Parenteral)
- 05 Mar 2020 Alnylam Pharmaceuticals and Vir Biotechnology expands collaboration to develop and commercialise RNA interference therapeutics for COVID-2019 infections and Coronavirus infections
- 05 Mar 2020 Early research in Coronavirus infections in USA (Parenteral)